Skip to content

Stock·NASDAQ·Healthcare

Natera, Inc. (NTRA)

$273.40 -16.52 (-5.70%)
At close: Nov 20, 4:00 PM EST
Hold
45 / 100
CleaRank Financial AI scorei
Market cap
$39.64B
P/E
n/m
Dividend yield
No dividend
Street target
$405.00median of 22 analysts
52-week range
$181.00 $437.41

What moved Natera, Inc. (NTRA)

Updated . Market figures as of November 20, 2026.

Was it the market or the company?

On November 20, 2026, NTRA fell 5.70%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.

The move was in line with the market. NTRA's one-year beta to SPY is 1.42, so SPY's -3.64% would on average have meant -5.17% for NTRA, close to what it did (0.5 percentage points more).

So most of the day's move came with the market; the dated news below is the company-specific backdrop, not the main driver of that session.

Over the last 20 sessions NTRA is down 32.32% against -9.23% for SPY, 23.1 percentage points behind it.

The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)

Moves to November 20, 2026, side by side
That day 5 sessions 20 sessions
NTRA -5.70% -14.32% -32.32%
S&P 500 (SPY) -3.64% -8.56% -9.23%
Nasdaq 100 (QQQ) -5.67% -10.51% -13.62%
Health care sector (XLV) -0.12% -6.15% -1.14%

Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.

In the news

  • Investing.com reported that Natera used the Jefferies Global Healthcare Conference to lay out a larger growth plan while it manages a CEO transition. The company flagged near-term cost pressure, reimbursement work and a long runway to its revenue goals.

    · Reported · Source: Investing.com

What changed since November 19, 2026

  • CleaRank score: 47/100 on November 19, 2026, 45/100 on November 20, 2026 (still Hold).

After moves like this

NTRA fell 5.70% on November 20, 2026. Its typical daily move over the 60 trading days before was 1.35%. Between March 9, 2022 and November 20, 2026 (1,181 trading days) it fell at least that much in one day 36 times before.

What followed earlier moves of this size
After the move Cases Median change Range
5 trading days later 35 +2.86% -15.45% to +37.17%
20 trading days later 32 +7.98% -15.24% to +38.76%
60 trading days later 31 +17.88% -27.30% to +85.42%

The close on November 20, 2026 is 37.29% below the highest close of the last 252 trading days ($436.00 on October 29, 2026). It is the lowest close since that high. Before that high, the last day it closed at least this far below its highest close of the 252 trading days to that day was October 30, 2023.

These figures describe what happened after earlier moves in that period. They are not a forecast.

01

NTRA stock today, November 22, 2026: price, news and analyst targets

As of November 20, 2026, Natera, Inc. (NTRA) trades at $273.40. Wall Street's median 12-month price target is $405.00 across 22 analysts, 48.1% above the price. CleaRank rates it Hold with a score of 45/100.

Natera's stock fell 5.70% on November 20, 2026, closing at $273.40, and now sits just 0.13% above its 200-day average of $273.05, the nearest support on the chart. The drop extends a sharp slide: the price is 27.19% below its 50-day average and 17.50% below its 20-day exponential average, with the 14-day RSI at 26.2, which places the stock in oversold territory. The sell-off comes after a 14.59% drop in the first session following the November 5, 2026 report, when adjusted EPS of -$0.42 missed the -$0.28 estimate by 50.00%. Analysts remain broadly positive, with 20 of 22 rating the stock Buy, and the median 12-month target is $405.00.

Why the stock has dropped

The stock has moved sharply lower over the past month, down 33.86%, after the November 5, 2026 report. Adjusted EPS of -$0.42 was a miss against the -$0.28 estimate, and the stock fell 14.59% in the first session after the report. The November 16, 2026 session also saw a 9.59% fall to $288.48, and the November 20, 2026 session took the close to $273.40. Investing.com reported on November 18, 2026 that Natera used the Jefferies Global Healthcare Conference to lay out a larger growth plan while managing a CEO transition, and that the company flagged near-term cost pressure, reimbursement work and a long runway to its revenue goals. The report is a press item and the company has not confirmed it, so the reasons for the sell-off are not settled.

Growth and profitability

Revenue grew 34.10% in the latest quarter compared with a year earlier, well ahead of the sector median of 8.1%. The company is still loss-making, with a net profit margin of -5.7% and an operating margin of -8.54%, and return on equity is -10.55%, below the sector median of 7.3%. Its debt-to-equity ratio is 0.13. Analysts expect revenue to rise 30.7% this fiscal year to about $3.0B, but they forecast EPS of -$1.56 for this year and -$0.35 for next year, so the path to profit is still a long way off.

Valuation against the sector

At $39.6B in market value and a price-to-sales ratio of 14.64, the stock trades at a premium to the sector median P/S of 3.4, a gap of 330.6%. The P/E ratio is not meaningful because reported earnings per share over the last 12 months are -$1.12. Insiders have sold $420.3M of stock over the last 18 months across 174 sales, with no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than purchases would be.

CleaRank score 45/100 (Hold). 8 of 17 checks pass: trend 2 of 4, momentum 0 of 3, valuation and quality 0 of 3, analysts 3 of 3, track record 3 of 4.

About Natera

Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners.

02

NTRA stock news

  • Growth plan and CEO transition

    · Investing.com

    Investing.com reported on November 18, 2026 that Natera laid out a larger growth plan at the Jefferies conference while managing a CEO transition, and flagged near-term cost pressure and reimbursement work. The report is not company-confirmed, and the cost warning is the part most likely to weigh on the stock.

  • Earnings miss and sharp reaction

    ·Earnings report

    Natera's adjusted EPS of -$0.42 on November 5, 2026 missed the -$0.28 estimate by 50.00%, and the stock fell 14.59% in the next session. This is the event that set the current downtrend.

  • Baird keeps Outperform

    ·Baird

    Baird kept its Outperform rating on November 9, 2026, adding to the view that the analyst base remains supportive after the miss.

  • JP Morgan keeps Overweight

    ·JP Morgan

    JP Morgan kept its Overweight rating on November 6, 2026, one day after the earnings report.

03

NTRA price target 2026

The base case is that the stock keeps trading in a wide range while it tests the 200-day average near $273.05. Holding that average would keep the trend intact, with the price above its 200-day average but below its 50-day one. A recovery toward the 20-day average near $331.39 would need the sell-off to ease and sentiment to steady after the earnings miss. Analysts' targets run from $280.00 to $500.00, with a median of $405.00, so the widest gap between the price and the analyst view remains. A close well below the 200-day average would put the 52-week low of $181.00 back in view and would challenge the analysts' revenue growth expectation of 30.7% for this fiscal year.

Analyst targets and ratings

12-month price targets

Low $280.00 Median $405.00 (+48.1%) High $500.00

Ratings

Buy 20 Hold 2 Sell 0 3 months ago: 19 of 22 buy

Recent rating actions

Recent analyst rating actions on NTRA
Date Firm Action Rating
Nov 9, 2026 Baird Maintains Outperform
Nov 6, 2026 JP Morgan Maintains Overweight
Nov 6, 2026 Evercore ISI Group Maintains Outperform
Oct 27, 2026 BTIG Maintains Buy
Oct 19, 2026 Canaccord Genuity Maintains Buy
Oct 14, 2026 JP Morgan Maintains Overweight
04

NTRA support and resistance levels

Support sits first at the 200-day average of $273.05, which the price is testing now; a close below it would move the focus to the 52-week low of $181.00. Resistance comes first at the 20-day exponential average of $331.39, which the price sits well below. The next resistance is the 50-day average of $375.52, and the 52-week high of $437.41 is the furthest level above the price.

NTRA support and resistance levels
Level What it is Price From the price
Resistance 3 52-week high $437.41 +60.0%
Resistance 2 50-day moving average $375.52 +37.4%
Resistance 1 20-day exponential average $331.39 +21.2%
Price November 20, 2026 $273.40
Support 1 200-day moving average $273.05 -0.1%
Support 2 52-week low $181.00 -33.8%

Technical indicators

Technical rating Neutral 1 of 4 signals bullish
  • RSI Oversold
  • SMA cross Bullish
  • Price vs SMA Bearish
  • MACD Bearish
Momentum Oversold
26.214-day RSI
Oversold <30 Neutral Overbought >70
MACD (12, 26) -28.90 Bearish
Trend Golden cross
-27.2%price against the 50-day average
200-day $273.05 50-day $375.52 Price $273.40
Price against the 200-day +0.1% Bullish

NTRA technical analysis in depth

Volatility, momentum, trend strength and the price levels that matter for NTRA, calculated by CleaRank from daily bars to November 20, 2026.

Volatility

On the 20-day Bollinger Bands (2 standard deviations) the bands run from $242.31 to $452.34 around a middle of $347.32, and NTRA's close of $273.40 sits near the lower band.

The bands are wider than on 99% of the last 120 sessions: volatility is high for NTRA.

The 14-day average true range is $20.96, or 7.7% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 11.5% from the close.

Momentum and volume

The 14-day stochastic reads 1 (signal line 6): the close is near the bottom of its two-week range, an oversold zone.

The MACD line (12, 26) is -28.90 against a signal line (9) of -21.25, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 15 sessions ago.

Volume in the latest session was 0.6 times its 20-day average, a light session.

Trend strength

The 14-day ADX is 43: a trending market, with sellers in control (+DI 12, -DI 38).

On the weekly chart the 10-week average ($370.79) is above the 40-week average ($273.45), a rising longer-term trend, and the weekly RSI is 42.

Key levels

The nearest resistance from the price history is $299.01 (+9.4%): the price turned here 3 times, most recently on November 6, 2026.

The nearest support is $249.99 (-8.6%): the price turned here 6 times, most recently on July 29, 2026.

The largest swing of the last 120 sessions ran up from $204.16 (June 3, 2026) to $437.41 (October 6, 2026); the nearest Fibonacci retracement to the price is the 78.6% level at $254.08.

Classic pivot points for the next session, from November 20, 2026: pivot $277.89, resistance $283.92 and $294.44, support $267.37 and $261.33.

NTRA key price levels
Level Price From the price What it is
Upper Bollinger Band $452.34 +65.4% 20-day average + 2 standard deviations
Fibonacci 23.6% $382.36 +39.9% retracement of the rise from $204.16 to $437.41
Fibonacci 38.2% $348.31 +27.4% retracement of the rise from $204.16 to $437.41
Resistance (swing high) $343.18 +25.5% a swing high set on August 27, 2026
Resistance (swing high) $321.01 +17.4% the price turned here 2 times, most recently on August 31, 2026
Fibonacci 50.0% $320.78 +17.3% retracement of the rise from $204.16 to $437.41
Resistance (swing high) $299.01 +9.4% the price turned here 3 times, most recently on November 6, 2026
Pivot R2 (classic) $294.44 +7.7% next-session level
Fibonacci 61.8% $293.26 +7.3% retracement of the rise from $204.16 to $437.41
Pivot R1 (Fibonacci) $284.21 +4.0% 38.2% of the last range above the pivot
Pivot R1 (classic) $283.92 +3.8% next-session level
Pivot point $277.89 +1.6% average of the last high, low and close
Price $273.40 close, November 20, 2026
Pivot S1 (Fibonacci) $271.56 -0.7% 38.2% of the last range below the pivot
Pivot S1 (classic) $267.37 -2.2% next-session level
Pivot S2 (classic) $261.33 -4.4% next-session level
Fibonacci 78.6% $254.08 -7.1% retracement of the rise from $204.16 to $437.41
Support (swing low) $249.99 -8.6% the price turned here 6 times, most recently on July 29, 2026
Lower Bollinger Band $242.31 -11.4% 20-day average - 2 standard deviations
Support (swing low) $221.59 -19.0% the price turned here 8 times, most recently on June 12, 2026
Support (swing low) $189.55 -30.7% the price turned here 8 times, most recently on May 15, 2026

Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.

05

NTRA stock price and trading

NTRA share price

Start $225.55 Nov 20, 2025
Latest close $273.40 Nov 20, 2026
High $436.00 Oct 29, 2026
Low $182.65 Mar 27, 2026
06

NTRA fundamentals and valuation

Key statistics

Market Cap
39.64B
P/E Ratio
n/m
EPS (TTM)
-$1.12
Dividend Yield
No dividend
52 Week High
437.41
52 Week Low
181.00

NTRA against the Healthcare sector

P/S ratio 301% above the median
NTRA
13.6x
Sector median
3.4x
Revenue growth, year on year 26.0 points above the median
NTRA
34.1%
Sector median
8.1%
Return on equity 17.9 points below the median
NTRA
-10.6%
Sector median
7.3%

Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, NTRA trades at 13.63x, far above the sector median of 3.40x.

Return vs XLV: Since Jun 11, 2025, NTRA has gained 64.0% against a gain of 30.6% for XLV.

Performance against XLV

NTRA XLV

Revenue and earnings

Revenue, 12 months
$2.9B
Net income, 12 months
-$165M
Net margin
-5.7%
Revenue growth
+34.1%
latest quarter, year on year
FY2021-75% marginFY2022-67% marginFY2023-40% marginFY2024-11% marginFY2025-9% margin
Revenue Net income

Revenue growth: Revenue grew 35.9% in FY2025 to $2.3B, from $1.7B a year earlier.

Profit margin: The net margin was -9.0% in FY2025, up from -11.2% the year before.

Loss-making: NTRA lost $208M in FY2025.

Earnings reality check

Beat the estimate
2 of 6
6 reports in our data
Fell after a beat
1 of 2
first session after the report
Average surprise
-22.0%
actual EPS against the estimate
Avg. first-session move
-0.5%
the stock, after the report
EPS surprise
First-session move
May '25Aug '25Nov '25May '26Aug '26Nov '26

Earnings record: NTRA beat the analyst estimate in 2 of the 6 reports in our data.

Market reaction: The stock fell in the first session after 1 of those 2 beats, so a beat has not been enough on its own.

NTRA earnings surprises and the stock's reaction
Report Estimate Actual Surprise First session 5 sessions
Nov 5, 2026after close -$0.28 -$0.42 -50.00% -14.59% -11.22%
Aug 6, 2026after close -$0.53 -$0.47 +11.32% +21.37% +17.11%
May 7, 2026after close -$0.55 -$0.60 -9.09% -11.64% -10.42%
Nov 6, 2025after close -$0.35 -$0.64 -82.86% +0.55% +1.10%
Aug 7, 2025after close -$0.59 -$0.74 -25.42% +7.70% +12.31%
May 8, 2025after close -$0.66 -$0.50 +24.24% -6.53% -8.10%
07

NTRA price history and drawdowns

Risk profile

Beta
1.52
against the S&P 500; 1 moves with the market
Daily volatility
4.27%
30-day standard deviation
52-week range
$273.40
$181.00 36% of the way up $437.41

Worst falls and recoveries

Worst fall, last 10 years
-76.6%
September 2021 to May 2022
Recovery
28 months
back at the old peak by September 2024
From the 10-year high
-37.3%
highest close, October 2026
1-year holds that gained
83%
of every 1-year window

Growth of $10,000

NTRA today
$232,879
from $10,000 in December 2016
S&P 500 today
$36,764
the same $10,000 in SPY, dividends reinvested
Ahead of the index by
$196,115
6.3x the index result
Total change
+2,229%
23x the starting amount
NTRA S&P 500 (SPY)

Against the market: NTRA beat the S&P 500 over this period: $232,879 against $36,764.

A $10,000 investment in NTRA in December 2016 would be worth about $232,879 today, compared with about $36,764 for the same investment in the S&P 500 benchmark with its dividends reinvested.

08

NTRA stock price prediction 2030

NTRA Stock Price Prediction 2030: Simulated Scenarios

Price today
$273
Base case, 2030
$424
1.6x over 4 years
Range, 2030
$118 to $1,529
10th to 90th percentile

CleaRank's simulation projects a price near $424 for NTRA by 2030 in the base case, from $273 today (1.6x over 4 years). The 10th-percentile path ends near $118. These are outcomes of a Monte Carlo simulation run on NTRA's historical return distribution, not price targets, and they assume no dividends are reinvested.

NTRA simulated price paths by year
Year 10th percentile Base case 90th percentile range base today
2027 $161 $305 $579
2028 $138 $341 $843
2029 $125 $380 $1,154
2030 $118 $424 $1,529
09

NTRA insider trading

NTRA insider trading

Bought
None
no open-market buys
Sold
$420.3M
174 open-market sales
Insiders filing
17
over the last 18 months
Average trade
$2.4M
buys and sales together

Month by month

Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26Nov '26

Net insider selling: No insider bought NTRA shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.

Insider transactions in NTRA
Date Insider Type Shares Value
Nov 6, 2026
Jonathan Sheena
Director
Sell 3.2K $995.4K
Nov 3, 2026
Michael Burkes Brophy
Chief Financial Officer
Sell 795 $314.0K
Nov 2, 2026
Steven Leonard Chapman
Chief Executive Officer
Sell 3.8K $1.6M
Nov 2, 2026
Solomon Moshkevich
Officer
Sell 3.4K $1.4M
Nov 2, 2026
Matthew Rabinowitz
Officer and Director
Sell 748 $299.2K
Nov 2, 2026
Daniel A Rabinowitz
Officer
Sell 341 $136.4K
Nov 2, 2026
John Fesko
President
Sell 302 $120.8K
Nov 2, 2026
Jonathan Sheena
Director
Sell 112 $44.8K
Oct 28, 2026
Steven Leonard Chapman
Chief Executive Officer
Sell 5.7K $2.4M
Oct 28, 2026
Daniel A Rabinowitz
Officer
Sell 1.9K $771.6K
10

NTRA stock forecast: questions people ask

NTRA Forecast: Frequently Asked Questions

What is the NTRA stock forecast?
The analysts' median 12-month price target is $405.00, which is 48.1% above the current price, with targets ranging from $280.00 to $500.00 across 22 analysts. The nearest level below the price is the 200-day average at $273.05, and the nearest level above is the 20-day exponential average at $331.39. These targets are analyst forecasts, not CleaRank's own.
What is the NTRA price target?
The median 12-month analyst target is $405.00, with the lowest at $280.00 and the highest at $500.00. The consensus rating is Buy. The stock closed at $273.40, which is 32.5% below the median target.
Is NTRA a buy or sell today?
Analysts rate the stock Buy on consensus, with 20 of 22 rating it buy or strong buy, 2 rating it hold and none rating it sell. CleaRank rates the stock Hold with a score of 45/100. The price is 0.13% above its 200-day average and 27.19% below its 50-day average, and the 14-day RSI of 26.2 is in the oversold zone.
Why did Natera stock fall after its latest report?
The stock fell 14.59% in the first session after the November 5, 2026 report, when adjusted EPS of -$0.42 missed the -$0.28 estimate by 50.00%. No cause beyond the miss itself is documented, so the reason for the reaction is not settled.
How has NTRA performed over the past year?
Over the past year the stock is up 21.21%, but over the past month it is down 33.86%. Over six months it is up 34.55%, so the recent fall has erased part of the longer gain.
Are insiders selling NTRA shares?
Insiders sold $420.3M of stock over the last 18 months in 174 sales, and made no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares.
How risky is NTRA compared with the market?
The stock has a beta of 1.52 against the S&P 500, and its typical daily move is 4.27%. On November 20, 2026 it fell 5.70%, and its typical daily move over the 60 sessions before was 1.35%.

How these figures are computed, and where the data comes from: CleaRank methodology.

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. The stock analysis and AI-generated signals presented for NTRA are for educational and informational purposes only and do not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. Simulated scenarios and historical performance figures shown are hypothetical and hindsight-based. They do not represent actual trades made by CleaRank or its affiliates. Stock prices can be volatile and are subject to market, economic, and company-specific risks. Market data is provided "as-is" and may be delayed by up to a minute. We do not guarantee the accuracy, completeness, or timeliness of any data. You should never invest money you cannot afford to lose. Past performance does not guarantee future results. Consult a qualified financial advisor before making any investment decisions. Analysis generated on November 22, 2026.